Ionis Pharmaceuticals, Inc.
IONS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $705,138 | $787,647 | $587,367 | $810,456 |
| % Growth | -10.5% | 34.1% | -27.5% | – |
| Cost of Goods Sold | $11,215 | $9,133 | $14,116 | $10,842 |
| Gross Profit | $693,923 | $778,514 | $573,251 | $799,614 |
| % Margin | 98.4% | 98.8% | 97.6% | 98.7% |
| R&D Expenses | $901,530 | $899,625 | $833,000 | $643,000 |
| G&A Expenses | $267,500 | $232,600 | $150,300 | $170,900 |
| SG&A Expenses | $267,500 | $232,600 | $150,295 | $170,900 |
| Sales & Mktg Exp. | $0 | $0 | -$5 | $0 |
| Other Operating Expenses | -$26 | $19 | $147 | $15,900 |
| Operating Expenses | $1,169,004 | $1,132,244 | $983,442 | $829,800 |
| Operating Income | -$475,081 | -$353,730 | -$410,191 | -$30,186 |
| % Margin | -67.4% | -44.9% | -69.8% | -3.7% |
| Other Income/Exp. Net | $15,013 | $19,765 | $152,206 | $1,038 |
| Pre-Tax Income | -$460,068 | -$333,965 | -$257,985 | -$29,148 |
| Tax Expense | -$6,171 | $32,321 | $11,737 | -$551 |
| Net Income | -$453,897 | -$366,286 | -$269,722 | -$28,597 |
| % Margin | -64.4% | -46.5% | -45.9% | -3.5% |
| EPS | -3.04 | -2.56 | -1.9 | -0.2 |
| % Growth | -18.8% | -34.7% | -850% | – |
| EPS Diluted | -3.04 | -2.56 | -1.9 | -0.2 |
| Weighted Avg Shares Out | 149,514 | 143,000 | 141,848 | 141,021 |
| Weighted Avg Shares Out Dil | 149,514 | 143,190 | 141,848 | 141,021 |
| Supplemental Information | – | – | – | – |
| Interest Income | $107,022 | $89,041 | $25,331 | $10,044 |
| Interest Expense | $90,451 | $81,457 | $8,122 | $9,349 |
| Depreciation & Amortization | $21,990 | $22,498 | $22,105 | $19,560 |
| EBITDA | -$353,721 | -$235,870 | -$227,758 | -$5,188 |
| % Margin | -50.2% | -29.9% | -38.8% | -0.6% |